Physician profile
Amber D Easley
NPI 1922548981
$4,860.45
in general payments reported to CMS, 2019-2025
25 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $310 · 2022: $553 · 2023: $3,514 · 2024: $174 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $3,345 · Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $3,344.60 |
| Food and Beverage | $652.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $3,344.60 | 2023 | Rs-Lbg/Fbg, Rs 4i Plus Sequential Stimulator |
| Biohaven Pharmaceutical Holding Company LTD. | $179.69 | 2022 | |
| Medtronic, INC. | $156.82 | 2025 | Synchromedii |
| Abbvie INC. | $155.52 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.73 | 2022-2024 | Relistor |
| Spinal Simplicity, LLC | $134.55 | 2025 | Ha Minuteman G3-R |
| Collegium Pharmaceutical, INC. | $112.49 | 2021-2023 | Belbuca |
| Abbott Laboratories | $90.30 | 2022-2023 | Eterna |
| Tersera Therapeutics LLC | $65.36 | 2021-2022 | |
| Grt US Holding, INC. | $60.85 | 2021-2022 | |
| Amgen INC. | $56.45 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $51.86 | 2022-2023 | Zilretta, Iovera |
| Scilex Pharmaceuticals INC. | $41.08 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $36.76 | 2021 | |
| Relievant Medsystems, INC. | $35.48 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acacia Pharma INC | $34.07 | 2021 | |
| Biodelivery Sciences International, INC. | $26.84 | 2021 | |
| Pacira Therapeutics, INC. | $24.17 | 2021 | |
| Lundbeck LLC | $22.18 | 2023 | Vyepti |
| Vertex Pharmaceuticals Incorporated | $18.71 | 2024 | |
| Biotronik Nro, INC. | $17.32 | 2025 | Prospera |
| Nalu Medical, INC. | $16.43 | 2024 | Nalu Neurostimulation System |
| Spr Therapeutics, INC | $14.50 | 2023 | Sprint Pns System |
| Lilly USA, LLC | $14.36 | 2022 | |
| Boston Scientific Corporation | $14.33 | 2024 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Easley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.